|
PEX13 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.01500055424719E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.89079995894082E-09 |
| Normal-vs-Stage2 |
1.85180000222829E-08 |
| Normal-vs-Stage3 |
2.49877896152384E-12 |
| Normal-vs-Stage4 |
7.76689823567267E-12 |
| Stage1-vs-Stage2 |
1.532760E-01 |
| Stage1-vs-Stage3 |
6.737800E-02 |
| Stage1-vs-Stage4 |
3.180800E-03 |
| Stage2-vs-Stage3 |
9.356400E-01 |
| Stage2-vs-Stage4 |
4.910800E-01 |
| Stage3-vs-Stage4 |
3.087000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.46650033730589E-10 |
| Normal-vs-AfricanAmerican |
9.683700E-03 |
| Normal-vs-Asian |
3.85520000367734E-08 |
| Caucasian-vs-AfricanAmerican |
1.451970E-02 |
| Caucasian-vs-Asian |
9.707000E-01 |
| AfricanAmerican-vs-Asian |
5.121700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.17760023954361E-10 |
| Normal-vs-Female |
1.64368518795754E-12 |
| Male-vs-Female |
1.894000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.64289948101759E-10 |
| Normal-vs-Age(41-60Yrs) |
1.83850046298062E-10 |
| Normal-vs-Age(61-80Yrs) |
3.80450115855524E-11 |
| Normal-vs-Age(81-100Yrs) |
3.362800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.401700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.722700E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.245800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.434000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.950200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.312400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.241000E-03 |
| Classical-VS-Follicular |
2.035400E-01 |
| Classical-VS-Other |
6.100800E-01 |
| Classical-VS-Normal |
1.94460000324526E-08 |
| Tall-VS-Follicular |
1.957590E-01 |
| Tall-VS-Other |
5.005400E-01 |
| Tall-VS-Normal |
1.81179959923838E-10 |
| Follicular-VS-Other |
9.468400E-01 |
| Follicular-VS-Normal |
8.37049984880878E-10 |
| Other-VS-Normal |
6.101300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.88657986402541E-15 |
| Normal-vs-N1 |
3.49659999843155E-08 |
| N0-vs-N1 |
7.508800E-01 |
|
|
